Re: 'Colistin plus meropenem for carbapenem-resistant gram-negative infections: in vitro synergism is not associated with better clinical outcomes'-Author's reply.

Nutman, A; Carmeli, Y

Re: 'Colistin plus meropenem for carbapenem-resistant gram-negative infections: in vitro synergism is not associated with better clinical outcomes'-Author's reply.

Nutman, A; Carmeli, Y.

Nutman A; National Institute for Infection Control and Antibiotic Resistance, Tel Aviv Medical Centre, and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: amirn@tlvmc.gov.il.
Carmeli Y; National Institute for Infection Control and Antibiotic Resistance, Tel Aviv Medical Centre, and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Clin Microbiol Infect ; 26(9): 1275, 2020 09.

Article en En | MEDLINE | ID: mdl-32464182

Asunto(s)

Infecciones por Acinetobacter; Colistina; Infecciones por Acinetobacter/tratamiento farmacológico; Antibacterianos/farmacología; Antibacterianos/uso terapéutico; Carbapenémicos/farmacología; Humanos; Meropenem/farmacología

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por Acinetobacter / Colistina Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google